Evidence map›Paper›PMID 31694697›Full record

ArticleCritical care (London, England)2019

Effect of tranexamic acid on mortality in patients with haemoptysis: a nationwide study.

Takahiro Kinoshita, Hiroyuki Ohbe, Hiroki Matsui, Kiyohide Fushimi, Hiroshi Ogura, Hideo Yasunaga

Open access · goldAbstract read
In one paragraph

Article in Critical care (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Review
  4. Management of severe acute pulmonary haemorrhage in children.The Lancet. Child & adolescent health · 2025
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Takahiro KinoshitaDepartment of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, 2-15 Yamadaoka, Suita, 565-0871, Japan.
Hiroyuki OhbeDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan. hohbey@gmail.com.ORCID 0000-0001-8544-2569
Hiroki MatsuiDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Kiyohide FushimiDepartment of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medicine, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
Hiroshi OguraDepartment of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, 2-15 Yamadaoka, Suita, 565-0871, Japan.
Hideo YasunagaDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
The University of Osaka · JPThe University of Tokyo · JPDepartment of Health · IETokyo Medical and Dental University · JP

Funding

Ministry of Education, Culture, Sports, Science and Technology, Japan 17H04141Ministry of Health, Labour and Welfare 19AA2007Ministry of Health, Labour and Welfare H30-Policy-Designated-004
6 · The paper itself

Abstract

backgroundAlthough tranexamic acid is widely used in patients with haemoptysis, whether it improves mortality has not been well investigated. The aim of this study was to evaluate the effect of tranexamic acid on in-hospital mortality among patients with haemoptysis.

methodsThis was a retrospective study using data from the Japanese Diagnosis Procedure Combination inpatient database. We identified all cases of emergency admission due to haemoptysis from July 2010 to March 2017. Patients were divided into two groups: a control group, and a tranexamic acid group (those who received tranexamic acid on the day of admission). The primary outcome was in-hospital mortality, with secondary outcomes of hospital stay length and total healthcare cost. The data were evaluated using a propensity score matching analysis.

resultsAmong 28,539 included patients, 17,049 patients received tranexamic acid and 11,490 patients did not. Propensity score analysis generated 9933 matched pairs. Compared to the control group, patients in the tranexamic acid group had significantly lower in-hospital mortality (11.5% vs. 9.0%; risk difference, - 2.5%; 95% confidence interval (CI), - 3.5 to - 1.6%), shorter hospital stays (18 ± 24 days vs. 16 ± 18 days; risk difference, - 2.4 days; 95% CI, - 3.1 to - 1.8 days), and lower total healthcare costs ($7573 ± 10,085 vs. $6757 ± 9127; risk difference, $- 816; 95% CI, $- 1109 to - 523).

conclusionsTranexamic acid may reduce in-hospital mortality among patients with haemoptysis requiring emergency admission.

Indexed as

AgedAntifibrinolytic AgentsFemaleHemoptysisHospital MortalityHumansJapanMaleMiddle AgedPropensity ScoreRetrospective StudiesTranexamic AcidAntifibrinolytic AgentsTranexamic AcidCost-effectivenessHaemoptysisPropensity score matchingTranexamic acid

Identifiers

PMID31694697
PMCPMC6836388
OpenAlexW2985489873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.